This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A second view: Discussing the recent label expansion of LUMRYZ (sodium oxybate), for the treatment of cataplexy in patients over the age of 7.
Ticker(s): AVDLWho's the expert?
(Arizona Neurology and Sleep Center)
- Practicing board certified neurologist for nearly two decades and established the Arizona Neurology and Sleep Center in 2010.
- Manages 100 patients with psychomotor impairment caused by mental fatigue.
- Will review the Phase 2A pilot study of PH15, designed to explore the efficacy of PH15 on psychomotor performance as measured by reaction time in sleep-deprived participants.
Interview Goal to discuss the current treatment landscape and the potential of LUMRYZ (sodium oxybate), an oral therapy recently approved by the FDA for the treatment of cataplexy in patients over the age of 7.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
